Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR68 | Q15743 | 6/20 | 0.52 |
| ▸ | KCNH3 | Q9ULD8 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | IDH2 | P48735 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | BRS3 | P32247 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22261660 | 1.00 | GPR68 (0.52) | GPR68KCNH3NPSR1ADORA2AHTR2B | |
| SCHEMBL16489591 | 0.68 | KDM4C (0.60) | KCNH3MEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL3298289 | 0.67 | KCNH3 (0.73) | KCNH3NPSR1GAAAPPALDH1A1 | |
| SCHEMBL6727019 | 0.65 | NPSR1 (0.74) | GPR68KCNH3NPSR1ADORA2AHTR2B | |
| SCHEMBL16489564 | 0.65 | KDM4C (0.56) | KCNH3BRS3MEN1ALDH1A1HPGD | |
| SCHEMBL23139067 | 0.65 | KCNH3 (0.56) | KCNH3GAAAPP | |
| SCHEMBL15102205 | 0.64 | IDH2 (0.83) | KCNH3NPSR1IDH2NPC1RAB9A | |
| SCHEMBL29763357 | 0.64 | IDH2 (0.83) | KCNH3NPSR1IDH2NPC1RAB9A | |
| SCHEMBL22698976 | 0.64 | KMT2A (0.53) | NPSR1BRS3RAB9AMEN1ALDH1A1 | |
| SCHEMBL14869402 | 0.62 | NPSR1 (0.64) | GPR68KCNH3NPSR1ADORA2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12433895-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20240335448-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | PHARMARESROUCES (SHANGHAI) CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| US-11844758-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220354856-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12433895-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | GPR68 3124/4885KCNH3 4722/4885NPSR1 3594/4885 |
| US-11844758-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | GPR68 3124/4885KCNH3 4722/4885NPSR1 3594/4885 |
| US-20240335448-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | GPR68 3124/4885KCNH3 4722/4885NPSR1 3594/4885 |
| US-20220354856-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | GPR68 3124/4885KCNH3 4722/4885NPSR1 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.